N/A N=14 Advanced Image Guidance Utilized in Liver Surgery
Carcinoma, Hepatocellular
Primary: Successful Insertion of Ablation Antenna Into Target Lesion — 100 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery
Malignant Gastrointestinal Neoplasm · Malignant Peritoneal Neoplasm
Primary: Number of Patients Who Self-report Wearing the Consumer-based Activity Monitor at Least 16 Days of the 21 Day Period — 9 Participants
Phase 4 N=80 Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast
Plaque Psoriasis
Primary: Percentage of Participants With a PASI 75 Response at Week 12 — 41.6 percentage of participants
N/A N=140 Syncope Prediction Study
Vasovagal Syncope
Primary: Sensitivity of the Syncope Prediction Algorithm — 81; 2 Participants
N/A N=10 Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System
CRC
Primary: Number of Participants With Boston Bowel Preparation Scale( BBPS) >1 in All Colon Segments After the Use of MCS — 9 Participants
N/A N=75 Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health
Dentin Sensitivity
Primary: Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 4 — 142.41; 135.24; -6.28…
Phase 3 N=80 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Leukemia, Hairy Cell
Primary: Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Review — 36.3 Percentage of participants
Phase 4 N=54 Reversing Corticosteroid Induced Memory Impairment
Memory Impairment
Primary: The Rey Auditory Verbal Learning Test (RAVLT) — 45.741; 43.286 T Score
Phase 1 N=33 Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 16; 10; 0; 0 Participants
Phase 3 N=79 Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain
Pain, Postoperative
Primary: Pain Score With Activity — 3.5; 4 units on a scale — p=0.72
N/A N=9 Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Primary: Tumor Absorbed Dose — 3.01; 3.41 Gy
Phase 3 N=424 An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging
Liver Lesions
Primary: Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or…
N/A N=50 Cervical Ripening for Induction of Labor: Misoprostol Versus Oxytocin in Conjunction With Foley Balloon
Induction of Labor
Primary: Rate of Induction To Delivery — 732.19; 944.35 minutes — p=0.037
Phase 2 N=32 A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia
Anemia of Chronic Kidney Disease
Primary: Change in Hemoglobin From Baseline to the End of 8-week Treatment Period — 10.8; 11.1 g/dL
Phase 1 N=28 Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Total Alectinib — 107; 83.6; 85.5; 85.1 nanograms per milliliter (ng/mL)